Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

NCT01666314 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Orteronel
DRUG: Orteronel Placebo
DRUG: Prednisone

Sponsor

Millennium Pharmaceuticals, Inc.